OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

Trial Profile

OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Telbivudine (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms OPTIMA
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 02 May 2014 New source identified and integrated (German Clinical Trials Register; DRKS00005961)
    • 04 Mar 2014 Planned End Date changed from 1 Nov 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top